Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children

被引:0
|
作者
Erazmus, Michal [1 ]
Ruminska, Malgorzata [1 ]
Witkowska-Sedek, Ewelina [1 ]
Kucharska, Anna M. [1 ]
Stelmaszczyk-Emmel, Anna [2 ]
Majcher, Anna [1 ]
Pyrzak, Beata [1 ]
机构
[1] Med Univ Warsaw, Dept Paediat & Endocrinol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Lab Diagnost & Clin Immunol Dev Age, Warsaw, Poland
来源
关键词
sRANKL; OPG; sRANKL ratio; cardiovascular risk factors; obesity; children; LOW SERUM-LEVELS; INSULIN-RESISTANCE; RANK LIGAND; URIC-ACID; VASCULAR CALCIFICATION; METABOLIC SYNDROME; RISK-FACTORS; B LIGAND; OSTEOPROTEGERIN; ATHEROSCLEROSIS;
D O I
10.3389/fendo.2022.963467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionChildhood obesity contributes to the development of cardiovascular diseases. The molecular pathway - receptor activator of nuclear factor-kappa beta ligand (RANKL), its receptor RANK and osteoprotegerin (OPG) - takes part not only in bone metabolism but is also involved in the atherosclerosis process. RANKL stimulates osteogenic differentiation and calcification of vascular smooth cells. The associations between the OPG-sRANKL system and various cardiovascular risk factors were displayed. We aimed to evaluate the relationships between serum sRANKL (soluble RANKL) levels and the OPG/sRANKL ratio with cardiometabolic risk factors in overweight and obese children. Material and methodsThe study included 70 children with overweight and obesity (mean age 13.0 +/- 2.8) and 35 age-matched normal weight, healthy peers as a control group. In all patients, anthropometric measurements and laboratory tests were performed. Additionally, an oral glucose tolerance test (OGTT) was made only in overweight and obese children. Atherogenic and insulin resistance indices were calculated. ResultsOverweight and obese children had lower sRANKL levels compared to the control group (median 276.95 vs 325.90, p=0.011), and consequently a higher OPG/sRANKL ratio (0.02 vs 0.01, p = 0.013). The studied children in the lowest quartile of sRANKL levels had higher body weight, Body Mass Index, waist circumference and increased glucose and insulin levels 60 minutes after OGTT and higher uric acid values compared to children in the highest quartile. In multivariable linear regression analysis sRANKL negatively correlated only with uric acid (beta = - 0.508, p = 0.041). No association was found for the OPG/sRANKL ratio. ConclusionExcess fat mass seems to alter the OPG/RANKL ratio mainly by reducing serum sRANKL levels. The correlation between sRANKL and uric acid may suggest a contribution of the OPG-sRANKL system in the cardiometabolic process, but that observation should be confirmed in future studies.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Changes of Serum Soluble Receptor Activator for Nuclear Factor-κB Ligand after Glucocorticoid Therapy Reflect Regulation of Its Expression by Osteoblasts
    Kaneko, Kaichi
    Kusunoki, Natsuko
    Hasunuma, Tomoko
    Kawai, Shinichi
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : E1909 - E1917
  • [42] Expression of receptor activator of nuclear factor-κB ligand by B cells in response to oral bacteria
    Han, X.
    Lin, X.
    Seliger, A. R.
    Eastcott, J.
    Kawai, T.
    Taubman, M. A.
    ORAL MICROBIOLOGY AND IMMUNOLOGY, 2009, 24 (03): : 190 - 196
  • [43] The role of the receptor activator of nuclear factor-κB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism
    Nakchbandi, Inaam A.
    Lang, Robert
    Kinder, Barbara
    Insogna, Karl L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03): : 967 - 973
  • [44] Receptor Activator of Nuclear Factor-κB Ligand (RANKL) Expression in Hepatocellular Carcinoma With Bone Metastasis
    Atsushi Sasaki
    Kenji Ishikawa
    Naotsugu Haraguchi
    Hiroshi Inoue
    Tetsuya Ishio
    Kohei Shibata
    Masayuki Ohta
    Seigo Kitano
    Masaki Mori
    Annals of Surgical Oncology, 2007, 14 : 1191 - 1199
  • [45] Differential expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA in periodontal diseases
    Bostanci, N.
    Ilgenli, T.
    Emingil, G.
    Afacan, B.
    Han, B.
    Toz, H.
    Berdeli, A.
    Atilla, G.
    McKay, I. J.
    Hughes, F. J.
    Belibasakis, G. N.
    JOURNAL OF PERIODONTAL RESEARCH, 2007, 42 (04) : 287 - 293
  • [46] Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
    Trouvin, Anne-Priscille
    Goeb, Vincent
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 345 - 354
  • [47] Receptor activator of nuclear Factor-κB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis
    Sasaki, Atsushi
    Ishikawa, Kenji
    Haraguchi, Naotsugu
    Inoue, Hiroshi
    Ishio, Tetsuya
    Shibata, Kohei
    Ohta, Masayuki
    Kitano, Seigo
    Mori, Masaki
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (03) : 1191 - 1199
  • [48] Roles of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in periodontal health and disease
    Nagasawa, Toshiyuki
    Kiji, Makoto
    Yashiro, Reiko
    Hormdee, Doosadee
    He, Lu
    Kunze, Melanie
    Suda, Tomonari
    Koshy, Geena
    Kobayashi, Hiroaki
    Oda, Shigeru
    Nitta, Hiroshi
    Ishikawa, Isao
    PERIODONTOLOGY 2000, 2007, 43 : 65 - 84
  • [49] The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin:: Clinical implications
    Vega, Damaris
    Maalouf, Naim M.
    Sakhaee, Khashayar
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (12): : 4514 - 4521
  • [50] Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastases
    Saad, Fred
    Markus, Richard
    Goessl, Carsten
    BJU INTERNATIONAL, 2008, 101 (09) : 1071 - 1075